SCHEMBL6477343

SCHEMBL6477343

CCOC(=O)/C=C/c1ccc(OC)c(-c2cc3c(cc2OCc2cccc(OC)c2)C(C)(C)CCC3(C)C)c1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FDPS P14324 1/20 0.48
AKR1C3 P42330 1/20 0.46
ALOX5 P09917 1/20 0.45
MAPT P10636 1/20 0.45
MAOB P27338 1/20 0.45
CYP1A2 P05177 1/20 0.43
CYP3A4 P08684 1/20 0.43
CYP2D6 P10635 1/20 0.43
CYP2C9 P11712 1/20 0.43
HSD17B1 P14061 1/20 0.43
CYP2C19 P33261 1/20 0.43
HSD17B2 P37059 1/20 0.43
ACHE P22303 4/20 0.42
CA5A P35218 3/20 0.41
CA9 Q16790 3/20 0.41
CA12 O43570 2/20 0.41
CA4 P22748 2/20 0.41
CA6 P23280 2/20 0.41
CA7 P43166 2/20 0.41
CA14 Q9ULX7 2/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6477344 1.00 FDPS (0.48) FDPSAKR1C3ALOX5MAPTMAOB
SCHEMBL6473218 0.94 FDPS (0.45) FDPSAKR1C3ALOX5MAPTMAOB
SCHEMBL6473700 0.94 FDPS (0.45) FDPSAKR1C3ALOX5MAPTMAOB
SCHEMBL6472801 0.93 RXRA (0.48) FDPSAKR1C3ALOX5MAPTMAOB
SCHEMBL6472798 0.93 RXRA (0.48) FDPSAKR1C3ALOX5MAPTMAOB
SCHEMBL6472933 0.92 CA12 (0.49) FDPSAKR1C3MAPTMAOBACHE
SCHEMBL6472928 0.92 CA12 (0.49) FDPSAKR1C3MAPTMAOBACHE
SCHEMBL6477948 0.92 FDPS (0.50) FDPSMAPTMAOBACHECA5A
SCHEMBL6477944 0.92 FDPS (0.50) FDPSMAPTMAOBACHECA5A
SCHEMBL6472256 0.91 FDPS (0.51) FDPSMAOBCA5ACA9CA12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6924388-B2 Bicyclic aromatic compounds and pharmaceutical/cosmetic compositions comprised thereof GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) 2005-08-02 US disclosed
US-20040092594-A1 Bicyclic aromatic compounds and pharmaceutical/cosmetic compositions comprised thereof GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) 2004-05-13 US disclosed
US-6632963-B1 Are useful for the treatment of a wide variety of disease states, whether human or veterinary, for example dermatological, rheumatic, respiratory, cardiovascular and ophthalmological disorders, as well as for the treatment of GALDERMA RESEARCH & DEVELOPMENT S.N.C. (FR) 2003-10-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040092594-A1 Bicyclic aromatic compounds and pharmaceutical/cosmetic compositions comprised thereof AHR, TYR, MC1R FDPS 3696/4885AKR1C3 225/4885ALOX5 1283/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.